First-line treatments for metastatic non-small-cell lung cancer with sugemalimab plus chemotherapy: a China-based cost-effectiveness analysis.

Cejemly (sugemalimab) - CStone Pharma

http://www.ncbi.nlm.nih.gov/pubmed/42032906

Andong Li; Chaohao Shi; Chongqing Tan; Kehui Meng; Meiyu Wu; Xiaomin Wan; Yangke Yi; Zhongbiao Jiang; Zixuan Zhang

Apr 25, 2026